Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
Takeda Healthcare Philippines Inc. led by country manager Loreann Villanueva (seated, second from the left) and Otsuka-Solar ...
We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...
TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...
In line with the "We the UAE 2031" Vision, the summit focused on improving quality of life and advancing specialized care for Inflammatory Bowel Disease (IBD) ...
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing ...
Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. Takeda Pharmaceutical Co. (TAK) is a stock many investors are watching right ...
Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...
Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...
Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.
Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...